Benzinga’s News Roundup (SNTS, MRVL, NVO, AET, CIEN, NVDA)
December 30, 2009 10:08 AM
Santarus, Inc. (NASDAQ: SNTS) today announced that it has submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration (FDA) to begin a Phase III clinical program evaluating rifamycin SV MMX in patients with travelers` diarrhea. SNTS has increased 0.87% to $4.65. The 52-week trading range for Santarus is $1.05 - $5.82. Yesterday, SNTS closed at $4.61.
Marvell Technology Group Ltd. (NASDAQ: MRVL) was today upgraded by Kaufman Bros from Hold to Buy and price target increased from $20 to $25, citing Marvell is expected to see continued strong growth in its storage semiconductor business. Marvell Technology Group is currently trading at $20.45, up 0.94% in the pre-market. Yesterday, MRVL closed at $20.26. So far in 2009, MRVL gained over 200%.
Novo Nordisk’s A/S (ADR) (NYSE: NVO) formal feedback for Novo Nordisk A/S diabetes drug liraglutide was delayed by The Food and Drug Administration (FDA) but is expected within weeks, Reuters reported today. NVO is currently trading at $64, decreased by 1.05% in the pre-market session. The 52-week trading range for NVO is $41.35 - $70.00. So far in the current year, NVO gained over 25%.
Aetna Inc. (NYSE: AET) today announced that it expects to incur a fourth-quarter 2009 charges of approximately $60 million to $65 million related to job reductions and real estate actions. Aetna Inc. is currently trading at $32.22, declined by 1.95% in the pre-market session. The 52-week trading range for AET is $18.66 - $34.91. In the last six months, AET gained over 30%.
Ciena Corporation (NASDAQ: CIEN) today announced that it has received the Investment Canada Act approval related to CIENA's acquisition of Nortel Networks' Metro Ethernet Networks (MEN) business. Ciena has declined 1.10% to $10.81 in the pre-market. In the last six months, CIEN gained 5%. CIEN closed at $10.93 yesterday.
NVIDIA Corporation (NASDAQ: NVDA) was today upgraded by Kaufman Bros from Hold to Buy and price target increased from $14 to $22, citing a continued recovery in discrete graphical processing unit (GPU) sales which will benefit NVIDIA. NVDA has increased 1.72% to $18.33 in the pre-market session. The 52-week trading range for NVDA is $7.08 - $18.22. So far in the current year, NVDA gained over 120%.
